Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,273,815 papers from all fields of science
Search
Sign In
Create Free Account
Response Evaluation Criteria in Solid Tumors
Known as:
RECIST
An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
D. Le
,
D. Le
,
+55 authors
L. A. Diaz
Science
2017
Corpus ID: 206661248
Predicting responses to immunotherapy Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have…
Expand
Review
2017
Review
2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
L. Seymour
,
J. Bogaerts
,
+18 authors
E. D. Vries
The Lancet Oncology
2017
Corpus ID: 28450489
Review
2016
Review
2016
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
J. Rosenberg
,
J. Hoffman-Censits
,
+28 authors
R. Dreicer
The Lancet
2016
Corpus ID: 205980891
Highly Cited
2016
Highly Cited
2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
L. Fehrenbacher
,
A. Spira
,
+15 authors
A. Rittmeyer
The Lancet
2016
Corpus ID: 5749435
Highly Cited
2015
Highly Cited
2015
PD-1 blockade in tumors with mismatch repair deficiency.
J. Uram
,
Hao Wang
,
+16 authors
L. Diaz
Journal of Clinical Oncology
2015
Corpus ID: 20303375
LBA100 Background: Somatic mutations have the potential to be recognized as "non-self" immunogenic antigens. Tumors with genetic…
Expand
Review
2014
Review
2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
C. Robert
,
A. Ribas
,
+23 authors
A. Daud
The Lancet
2014
Corpus ID: 25938602
Review
2013
Review
2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid
,
C. Robert
,
+23 authors
A. Ribas
New England Journal of Medicine
2013
Corpus ID: 205095805
BACKGROUND The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune…
Expand
Review
2009
Review
2009
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
Hirokazu Watanabe
,
M. Okada
,
+7 authors
Y. Arai
Gan to kagaku ryoho. Cancer & chemotherapy
2009
Corpus ID: 36879985
This paper is an overview of the new response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1), with…
Expand
Highly Cited
2007
Highly Cited
2007
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new…
Haesun Choi
,
C. Charnsangavej
,
+6 authors
R. Benjamin
Journal of Clinical Oncology
2007
Corpus ID: 10307172
PURPOSE Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating gastrointestinal stromal tumors…
Expand
Review
2000
Review
2000
[New guidelines to evaluate the response to treatment in solid tumors].
F. Duffaud
,
P. Therasse
Bulletin du Cancer
2000
Corpus ID: 15541119
Anticancer agents go through a process by which their antitumor activity, on the basis of the amount of tumor shrinkage they…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE